Ipca Laboratories Ltd (IPCALAB) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Ipca Laboratories Ltd. reported 11% domestic business growth in Q4 and 12% for the full fiscal year FY25.
- The company ranked 16th among the top 20 fastest-growing pharmaceutical companies as per IQVIA, mid-March 2025.
- Market share improved by 9 basis points in Q4, reaching 2.07%, up from 1.8% in mid-March 2024.
- Growth in both acute and chronic segments outperformed the market.
- Increased metro city coverage post-COVID contributed to faster growth.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.